Business Context and Reporting Period
Company: ProQR Therapeutics N.V.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2015
Accounting Standards: International Financial Reporting Standards (IFRS)
Business Overview: ProQR is a clinical-stage biopharmaceutical company developing RNA-based therapeutics for severe genetic orphan disorders. The company has no commercial products and has not generated product revenue. Its primary focus is on QR-010 for Cystic Fibrosis (CF) and QR-110 for Leber's Congenital Amaurosis (LCA).
Key Financial Metrics
| Metric (€ in thousands) | 2015 | 2014 | 2013 |
|---|---|---|---|
| Other Income | 3,235 | 313 | 116 |
| Research & Development Costs | (23,401) | (10,267) | (2,569) |
| General & Administrative Costs | (6,837) | (6,507) | (786) |
| Operating Result | (27,003) | (16,461) | (3,239) |
| Finance Income/Expense | 6,171 | 4,334 | (14) |
| Net Loss | (20,832) | (12,127) | (3,253) |
| Cash and Cash Equivalents (Year End) | 94,865 | 112,736 | 4,129 |
| Total Assets | 100,109 | 115,247 | 4,504 |
| Total Liabilities | 10,310 | 5,843 | 4,593 |
| Shareholders' Equity | 89,799 | 109,404 | (89) |
| Accumulated Deficit | (36,630) | (15,798) | (3,671) |
Per Share Data (2015): Basic and diluted loss per share was €(0.89). Weighted average shares outstanding: 23,343,262.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 72% from €12.1 million in 2014 to €20.8 million in 2015.
- R&D Expense Surge: Research and development costs more than doubled to €23.4 million, driven by the initiation of Phase 1b clinical trials for QR-010, increased staff (72 FTEs in R&D vs. 40 in 2014), and costs for GMP compound production.
- Other Income Growth: Other income rose significantly to €3.2 million, primarily due to a €6.0 million grant from the European Union's Horizon 2020 program (€4.4 million recognized for ProQR) and continued funding from the Cystic Fibrosis Foundation Therapeutics (CFFT).
- Finance Income: Net finance income of €6.2 million was largely attributable to foreign exchange gains on U.S. dollar-denominated cash balances due to the strengthening of the dollar against the euro.
- Cash Position: Cash and cash equivalents decreased by €17.9 million to €94.9 million, reflecting higher operating burn rates partially offset by financing activities (government loans) and foreign exchange effects.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes existing cash resources (€94.9 million) are sufficient to fund operations through at least mid-2017. The company expects to continue incurring significant losses as it advances clinical trials for QR-010 and QR-110 and expands its pipeline.
Key Milestones:
- QR-010 (CF): Two global clinical trials (Phase 1b and Proof-of-Concept) are ongoing. Top-line data is expected in mid-to-late 2016.
- QR-110 (LCA): Pre-clinical development is complete; the company intends to start the first clinical trial in 2016.
Material Risks and Contingencies:
- Capital Needs: The company has no product revenue and relies on equity financing, grants, and loans. Future funding requirements are uncertain.
- Milestone Payments: The first commercial sale of QR-010 will trigger a milestone payment of approximately $80 million to CFFT, payable in installments. The company may not have sufficient funds to support this obligation upon approval.
- Regulatory and Clinical Risk: Success depends on clinical trial results, regulatory approvals (FDA/EMA), and the unproven nature of RNA repair technology.
- Intellectual Property: The company relies on licensed patents from third parties (e.g., Massachusetts General Hospital, Radboud University) and faces risks of infringement claims or license termination.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "mid-2017" liquidity estimate given the high burn rate (€24.2 million operating cash outflow in 2015).
- CFFT Agreement: Review the specific terms of the $80 million milestone payment obligation to CFFT and the company's plan to fund it upon commercialization.
- Clinical Trial Progress: Monitor enrollment rates and safety data for the QR-010 Phase 1b and Proof-of-Concept trials, with data expected in 2016.
- Grant Sustainability: Assess the reliance on non-recurring grants (Horizon 2020, CFFT) which contributed significantly to offsetting R&D costs in 2015.
- Foreign Exchange Impact: Note that 2015 financial results included significant FX gains; future results may vary based on currency fluctuations.